Phase III KEYNOTE-394 trial of Keytruda meets primary endpoint in hepatocellular carcinoma – Merck Inc

Merck Inc announced that the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib met its primary endpoint of overall survival (OS). The study found that treatment with Keytruda plus best supportive care resulted in a statistically significant improvement in OS compared with placebo plus best supportive […]

Antibody-targeted immunotoxins could help treat liver fibrosis

University of California – San Diego In mouse models of human disease, immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and cirrhosis. Effectively, this represents the use of an antibody-drug conjugate to target a feature of diseased tissue, an approach that is already in use in the management of solid tumours. Chronic alcohol […]

Intercept Pharmaceuticals Inc. announces updates to Ocaliva prescribing information for primary biliary cholangitis

Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351 medicalupdateonline.com is brought to you by International Medical Information. For more details, visit http://www.medicalimi.com Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot […]

Semaglutide leads to significant weight loss in Type 2 diabetes patients

Article by Bruce Sylvester. Patients diagnosed with type 2 diabetes and treated with weekly semaglutide have achieved an average weight loss of almost 10kg, researchers reported on March 2, 2021  in The Lancet. Put in other terms, two-thirds of subjects treated with weekly injections of a 2.4mg semaglutide lost at least 5% of their body weight and achieved significant improvement in […]